Baseline predictors of an early virologic response (EVR) in previously untreated patients undergoing boceprevir (BOC) triple therapy for HCV genotype 1 infection in German real-li…
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, C John, P Geyer, B Weber, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer · Zeitschrift für Gastroenterologie · 2015 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background: The achievement of EVR during triple therapy of chronic HCV genotype 1 (G1) infection with BOC has been identified as predictor of high SVR rates of up to 90% as well as a predictor to shorten triple therapy to 24 weeks. The present interim analysis of the NOVUS observational study was aimed to investigate EVR during BOC triple therapy in German real-life and to identify baseline predictors of EVR. Methods: From April 2012 until January 2014, 536 patients with G1 infection were recruited in the ongoing NOVUS study by 97 practices and hospitals in Germany. Patients were treated with pegylated interfer…
